Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1975 Mar;7(3):229–232. doi: 10.1128/aac.7.3.229

Varicella-Zoster Virus and Subcutaneous Cytarabine: Correlation of In Vitro Sensitivities to Blood Levels

Dawlat A Zaky *, Robert F Betts †, R Gordon Douglas Jr †, Kathleen Bengali †, Gary L Neil †
PMCID: PMC429116  PMID: 166610

Abstract

The susceptibility of 26 strains of varicella-zoster virus to cytarabine was tested in vitro by measuring reduction in number and size of plaques using human foreskin fibroblast cells. Most strains showed 50% reduction of plaque number by 0.125 μg of cytarabine per ml or less. Cytarabine levels in sera of 12 patients after a single subcutaneous injection of 50 mg/M2 exceeded this inhibitory level for a period of 75 min. Thus, the subcutaneous route is a potentially useful method of administration of cytarabine for antiviral drug trials.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bryson Y., Connor J. D., Sweetman L., Carey S., Stuckey M. A., Buchanan R. Determination of plaque inhibitory activity of adenine arabinoside (9-beta-D-arabinofuranosyladenine) for herpesviruses using an adenosine deaminase inhibitor. Antimicrob Agents Chemother. 1974 Jul;6(1):98–101. doi: 10.1128/aac.6.1.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fiala M., Chow A. W., Miyasaki K., Guze L. B. Susceptibility of herpesviruses to three nucleoside analogues and their combinations and enhancement of the antiviral effect of acid pH. J Infect Dis. 1974 Jan;129(1):82–85. doi: 10.1093/infdis/129.1.82. [DOI] [PubMed] [Google Scholar]
  3. Fiala M., Chow A., Guze L. B. Susceptibility of herpesviruses to cytosine arabinoside: standardization of susceptibility test procedure and relative resistance of herpes simplex type 2 strains. Antimicrob Agents Chemother. 1972 Apr;1(4):354–357. doi: 10.1128/aac.1.4.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hanka L. J., Kuentzel S. L., Neil G. L. Improved microbiological assay for cytosine arabinoside (NSC-63878). Cancer Chemother Rep. 1970 Dec;54(6):393–397. [PubMed] [Google Scholar]
  5. Marks M. I. Variables influencing the in vitro susceptibilities of herpes simplex viruses to antiviral drugs. Antimicrob Agents Chemother. 1974 Jul;6(1):34–38. doi: 10.1128/aac.6.1.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. McKelvey E. M., Kwaan H. C. Cytosine arabinoside therapy for disseminated herpes zoster in a patient with IgG pyroglobulinemia. Blood. 1969 Nov;34(5):706–711. [PubMed] [Google Scholar]
  7. Merigan T. C., Gregory D. F., Petralli J. K. Physical properties of human interferon prepared in vitro and in vivo. Virology. 1966 Aug;29(4):515–522. doi: 10.1016/0042-6822(66)90276-5. [DOI] [PubMed] [Google Scholar]
  8. RAPP F. INHIBITION BY METABOLIC ANALOGUES OF PLAQUE FORMATION BY HERPES ZOSTER AND HERPES SIMPLEX VIRUSES. J Immunol. 1964 Oct;93:643–648. [PubMed] [Google Scholar]
  9. RAPP F., VANDERSLICE D. SPREAD OF ZOSTER VIRUS IN HUMAN EMBRYONIC LUNG CELLS AND THE INHIBITORY EFFECT OF LODODEOXYURIDINE. Virology. 1964 Mar;22:321–330. doi: 10.1016/0042-6822(64)90023-6. [DOI] [PubMed] [Google Scholar]
  10. Stevens D. A., Jordan G. W., Waddell T. F., Merigan T. C. Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med. 1973 Oct 25;289(17):873–878. doi: 10.1056/NEJM197310252891701. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES